Pharmaceuticals News & Press Release Distribution

Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment

* Insilico's candidate demonstrated a favorable profile with good in vivo efficacy at low doses, efficient synthesis, and no need for co-administration with Ritonavir. * The candidate is intended to be used for the treatment of SARS-CoV-2 and its variants, along with other coronaviruses. * ...

2022-05-25 05:00 2231

Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment

ICP DAS - BMP will attend Medical Taiwan Expo 2022 in Taipei

TAIPEI, May 25, 2022 /PRNewswire/ -- ICP DAS - BMP (Biomedical Polymers), a Taiwanese medical TPU (thermoplastic polyurethane) supplier, will exhibit at Medical Taiwan 2022, an international medical, health, and care expo. The Medical Taiwan Expo 2022 will take place at the Taipei Nangang Exhibit...

2022-05-25 01:25 3477

ICP DAS - BMP will attend Medical Taiwan Expo 2022 in Taipei

Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment

* Insilico's candidate demonstrated a favorable profile with good in vivo efficacy at low doses, efficient synthesis, and no need for co-administration with Ritonavir. * The candidate is intended to be used for the treatment of SARS-CoV-2 and its variants, along with other coronaviruses. Insi...

2022-05-24 21:00 2434

Travecta Therapeutics Announces In-Person Presentation at 2022 BIO International Convention

SINGAPORE and PRINCETON, N.J., May 24, 2022 /PRNewswire/ -- Travecta Therapeutics, Pte Ltd., a private biopharmaceutical company pioneering transformative treatments for serious neurological conditions by utilizing a natural transport system in the blood-brain barrier ("BBB") as a novel delivery ...

2022-05-24 20:00 2158

Everest Medicines' Licensing Partner Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod's Potentially Best-in-Class Profile in Ulcerative Colitis

SHANGHAI, May 24, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) presented at Digestive Disease Week (DDW) 2022 detailed results from two pivotal studies that make up the ELEVATE UC Phase 3 registrational program evaluatin...

2022-05-24 19:00 1479

Everest Medicines' Licensing Partner Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod's Potentially Best-in-Class Profile in Ulcerative Colitis

SHANGHAI, May 24, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) presented at Digestive Disease Week (DDW) 2022 detailed results from two pivotal studies that make up the ELEVATE UC Phase 3 registrational program evaluatin...

2022-05-24 19:00 2146

New Study Shows Critical Role of 1,5-Anhydroglucitol (1,5-AG) in COVID-19 Pathogenesis by Binding to the COVID-19 Spike Protein

Study Findings Support Data Presented on the GlycoMark Blood Test at the Most RecentADA and AHA Scientific Sessions RALEIGH, N.C., May 24, 2022 /PRNewswire/ -- Precision Diabetes, Inc. A new study recently published inNature Metabolism shows that 1,5-anhydroglucitol (1,5-AG), a glucose-like me...

2022-05-24 19:00 1487

Pierre Fabre and EORTC open a large Phase III clinical study in the adjuvant setting of stage IIB-C melanoma

* First study conducted in the adjuvant setting with a combination of BRAF and MEK inhibitors in high-risk stage II BRAF V600E/K-mutant cutaneous melanoma * A global partnership between EORTC and Pierre Fabre to advance research in melanoma CASTRES, France and BRUSSELS, May 24, 2022 /PRNewswir...

2022-05-24 14:15 1648

RemeGen to Present Three Studies on Disitamab Vedotin at 2022 ASCO Annual Meeting

YANTAI, China, May 23, 2022 /PRNewswire/ -- RemeGen Co., Ltd. (9995.HK, SHA: 688331), a commercial-stage biotechnology company, today announced that three abstracts for disitamab vedotin (RC48) have been selected for poster discussions by the 2022 American Society of Clinical Oncology (ASCO) Ann...

2022-05-24 10:27 1785

SwipeRx secures US$27 Million in Series B Funding to accelerate growth across Southeast Asia

SINGAPORE, May 24, 2022 /PRNewswire/ -- SwipeRx (formerly mClinica Pharmacy Solutions),Southeast Asia's (SEA) leading platform for pharmacies, announced it has secured a Series B round ofUS$27 million in equity and debt to accelerate growth across SEA. The round was led byIndonesia's MDI Ventures...

2022-05-24 10:00 2002

HistoSonics Announces Agreement with GE Healthcare

HistoSonics Breakthrough Liver Therapy System to Utilize GE's LOGIQ™ E10 for Real-Time Imaging Guidance and Treatment Verification MINNEAPOLIS, May 23, 2022 /PRNewswire/ -- HistoSonics Inc., developer of a completely non-invasive platform using the science of histotripsy, today announced an agre...

2022-05-23 21:00 2762

HistoSonics Announces Agreement with GE Healthcare

Medison Pharma Announces Extension of Multi-territorial Agreement with Immunocore and Expansion into Australia and New Zealand

The latest geographic growth increases Medison's global footprint across 25 countries in four continents, further strengthening its commercial offering PETACH TIKVAH, Israel, May 23, 2022 /PRNewswire/ -- Medison Pharma ("Medison"), a global pharma company focused ...

2022-05-23 20:28 3127

VISEN Pharmaceuticals Announces Top-line Results of Phase 3 Trial of Once-Weekly Lonapegsomatropin, Demonstrating Superior Efficacy, Comparable Safety and Tolerability to Daily Growth Hormone

SHANGHAI, May 23, 2022 /PRNewswire/ -- VISEN Pharmaceuticals, an innovative biopharmaceutical company focused on endocrine diseases, today announced positive top-line results from its pivotal phase 3 trial, a randomized, open-label, active-controlled trial that compared lonapegsomatropin (TransCo...

2022-05-23 15:57 1271

Antengene Announces First Patient Dosed in the Phase I/II SWATCH Study of XPOVIO® (Selinexor) for the Treatment of B-Cell Non-Hodgkin Lymphomas

SHANGHAI and HONG KONG, May 23, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer...

2022-05-23 10:10 2676

Hanmi Fine Chemical Launches 'high-tech CDMO' Business

CDMO business initiated such as mRNA vaccine raw materials·peptides 10 billion KRW invested in Hanmi Fine Chemical facility expansion SEOUL, South Korea, May 22, 2022 /PRNewswire/ -- Hanmi Fine Chemical (hereinafter Hanmi FC) a subsidiary of Hanmi Pharmaceutical Group specializing in APIs(Active...

2022-05-23 08:32 1996

Hanmi Fine Chemical Launches 'high-tech CDMO' Business

Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma

-- European Commission Decision Anticipated within Approximately 60 Days -- NEWTON, Mass. and FLORENCE, Italy, May 21, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group ("Menarini")...

2022-05-21 01:19 9543

Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology

* Emerald study met both its primary end points of Progression-free survival (PFS) in overall population and in ESR1 mutated patients * PFS rate at 12 months with elacestrant was 22.32% vs. 9.42% with SOC in the overall population, and 26.76% vs. 8.19% in theESR1 mutation population * Data d...

2022-05-20 16:17 3035

Lipidor updates on Phase III study of AKP02 in treatment of psoriasis - half of patients now recruited

STOCKHOLM, May 20, 2022 /PRNewswire/ -- Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces that half of the patients have now been enrolled in the Phase III study of AKP02 skin spray for mild to moderate psoriasis, with the last patient expected to begin treatment inJune 2022. T...

2022-05-20 14:56 2344

Sirnaomics will present clinical study results and development strategy for Cancer RNA Therapeutics at the 2022 Pre-ASCO China Summit

GAITHERSBURG, Md. and SUZHOU, China, May 20, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the Company's Executive Director and Chief Medical O...

2022-05-20 12:31 2799

CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing

TIANJIN, China, May 19, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced that the World Health Organization ("WHO") has granted Emergency Use Listing ("EUL") for Convidecia™, CanSinoBIO's Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5...

2022-05-19 23:28 3415